Takeda merges with TAP

Takeda Pharmaceuticals has merged with the TAP company in an effort to boost its operations worldwide.

A 30-year joint venture partnership agreement was reached recently between the two businesses and the arrangements have progressed to the point where a merger was viewed as beneficial to both parties.

TAP sells a number of pharmaceutical products in North American markets and Takeda has suggested that the merger should help it to enhance it position in these crucial regions for the future of its business.

“The merger of TAP and Takeda represents a significant milestone in the integration of two successful companies, and we look forward to maximising future growth opportunities,” said Yasuchika Hasegawa, president of the Takeda Pharmaceutical Company.

Having been founded in 1781 in Japan, Takedo now has operations worldwide, including research and development facilities in London and Cambridge, and a manufacturing site in Ireland.